Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability and Dose Titration of ALKS 5461 in Healthy Subjects
NCT02068105Phase 1Completed
- Sponsor
- Alkermes
- Start
- Jan 2014
- Primary completion
- Mar 2014
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of buprenorphine + samidorphan in major depressive disorder (MDD) (6 arms), sponsored by Alkermes. Primary endpoint: Relative bioavailability of ALKS 5461 treatment groups at 21 days. Started Jan 2014; status: completed.
02
Drugs
buprenorphine + samidorphan
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT02068105.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02068105.